Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Harvard Business School
Queensland Health

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 9,586,940

  Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,586,940
Title:Methods for treatment of breast cancer nonresponsive to trastuzumab
Abstract: The present invention provides a method of treating breast cancer that is nonresponsive to treatment with trastuzumab, comprising administering to a subject in need of such treatment a therapeutically effective amount of compound N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydro- cyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or a pharmaceutically acceptable salt thereof.
Inventor(s): Waksal; Samuel (New York, NY), Chiang; Lillian (Princeton, NJ)
Application Number:14/801,335
Patent Claims:see list of patent claims

Details for Patent 9,586,940

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up KADMON CORORATION, LLC (New York, NY) 2031-12-27 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,586,940

Country Patent Number Publication Date
Canada 2860051 Jul 04, 2013
European Patent Office 2797628 Jul 29, 2015
European Patent Office 2797628 Nov 05, 2014
Japan 2015503568 Feb 02, 2015
United States of America 2015010545 Jan 08, 2015
United States of America 2015322046 Nov 12, 2015
World Intellectual Property Organization (WIPO) 2013101964 Jul 04, 2013
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.